about
Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increaseAcquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expressionPlant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro.Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan.Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesisThe naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in micePrognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosisProteome profiling in IL-1β and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis.Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivoUrinary proteomic pattern in female stress urinary incontinence: a pilot study.Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.Galectin-1 in melanoma biology and related neo-angiogenesis processes.Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice.Proteomic profiling identifies markers for inflammation-related tumor-fibroblast interaction.Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling.FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.Serum proteomic pattern in female stress urinary incontinence.STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer.Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis.FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.Proteome profiling of keratinocytes transforming to malignancy.Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins.The thiosemicarbazone MeNNMe induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibitionEGFR is required for FOS-dependent bone tumor development via RSK2/CREB signalingExpression of FGF8, FGF18, and FGFR4 in Gastroesophageal AdenocarcinomasProteomic identification of a marker signature for MAPKi resistance in melanomaHair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapyTelomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroupComputational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactionsIDO1+ Paneth cells promote immune escape of colorectal cancer
P50
Q28830269-17054EA2-A0ED-4809-A0E8-C2DF6069FD6CQ30365571-9E4D2CF6-BC4A-4868-8507-4B8ED22D1EC1Q34992804-1E5701C3-C4F1-487E-86C0-E536A2F252B4Q35050458-0E9DA8E8-5131-48DB-A098-915920F0941DQ35196919-2C4E1625-C94C-4B39-835F-D35D77E44EAFQ35232168-960F1BE0-A28E-4CAC-96DC-5214624AC0CEQ35799053-2429D360-8CB2-4235-92C1-041CCCFB0B8AQ36107360-C2839EF6-BB91-4214-9F88-4D80943A78AFQ36406271-901D81E0-19E3-4508-B29D-6F1C0D4BE68AQ37069163-A1C36A84-6589-40F5-B28C-86894DF84141Q37253610-B108727F-6466-4213-8D57-E55F7420B973Q37342332-F646B62C-5AAC-494D-907E-3ACCAD004BFBQ38720938-62A143FC-7409-48D8-B20F-F766F1F558DEQ38858546-B2C5B99D-37EC-4921-B3C1-E01C0BE98DACQ38974755-59CC3BB7-43DA-4EAB-AE65-840FF4BBBFE4Q39343382-FB54C288-9F54-43F1-B8F0-E5EDD8DBB7A2Q39592731-41A85110-4234-42BC-998F-2EF70F0F8C4CQ41361264-65590D0F-F8A3-4242-A896-0C6CF3EBA830Q46021284-5CF0393A-27AB-4FF1-9DCD-AFCD77DDC189Q47131461-44000F94-10C3-4202-9DBC-D775A83B8FCCQ47160915-1ECC9C44-1129-416F-8AE5-FD6C65EA752EQ47550183-517C6BE1-978A-4FAE-90E3-491EE9D5F394Q50116924-06E5805A-6C5F-48EA-9D86-ADE3B0784D4BQ50885630-203486AC-2307-4A6D-9763-E11F485FBF9EQ52596095-B9862427-790D-46F1-B928-0CDCFDB9477DQ53228203-FD9CC01E-F8F1-452E-BA2F-655857FBC60DQ55175737-8E0FFC7C-D13A-4D5D-B272-F77DC9B475D5Q57461787-D27C2F2F-425B-4354-B5EF-162F616BD744Q58550279-6AACF7E7-221E-4706-8DEA-D162A237D31CQ90133622-4AD0FFE8-9EC0-4068-9DCC-503FE0762A77Q91569472-4F58EDEB-1818-4689-B917-5A165BAEAD9BQ91890138-D73342C1-5F92-467F-A264-EA3238317EBEQ92128479-CC4590ED-4B1C-4079-833A-7741AA67D179Q92576910-C70D984F-D531-46D8-9F0B-1019E18FD24AQ95660974-EE64D11D-1F3B-407C-97E5-3E62A4003207
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1933-847X
@en
name
Thomas Mohr
@ast
Thomas Mohr
@en
Thomas Mohr
@es
Thomas Mohr
@nl
type
label
Thomas Mohr
@ast
Thomas Mohr
@en
Thomas Mohr
@es
Thomas Mohr
@nl
prefLabel
Thomas Mohr
@ast
Thomas Mohr
@en
Thomas Mohr
@es
Thomas Mohr
@nl
P106
P31
P496
0000-0002-1933-847X